Nurturing Our Relations: A Randomized Controlled Trial of Virtual Reality Indigenous Cultural Safety Training Compared to Control for Obstetric and Neonatal Care Nurses
NCT07925892, Not applicable, Not yet recruiting, Unity Health Toronto
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Nurturing Our Relations: A Randomized Controlled Trial of Virtual Reality Indigenous Cultural Safety Training Compared to Control for Obstetric and Neonatal Care Nurses | ClinicalTrials.gov |
| NCT number | NCT07925892 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 120 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Unity Health Toronto | ClinicalTrials.gov |
| Conditions | Quality of Nursing Care for Indigenous Patients | ClinicalTrials.gov |
| Interventions | Virtual Reality Indigenous Cultural Safety Training, Online Clinical Education on non-ICS topic | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Quality of relational Indigenous patient engagement as assessed by standardized patient using Quality of Health Care Provider Relationship and Communication Tool | Measured 10-12 weeks post intervention | The assessment of the quality of relational Indigenous patient engagement will be done by a trained Indigenous standardized patient during an in-person simulated patient encounter. Indigenous standardized patients will be trained to conduct assessments using structured tools and standardized during a series of initial and re-standardization training leading up to the assessment dates. Relational quality of care will be assessed using the Quality of Health Care Provider Relationship and Communication Tool. This tool has been piloted in previous work and consists of a 13 item scale adapted from existing patient scales and one stand alone item "Would you recommend this tool to family and friends?". The maximum score on the 13 item scale is 65 and the maximum score on the additional stand along item is "very highly recommend". Higher scores indicate a better outcome. | ClinicalTrials.gov |
| Primary | Assessment of clinical decision making during standardized Indigenous patient encounter using Adherence to Clinical Practice Guideline Assessment Tool. | Measured 10-12 weeks post intervention | Assessment of clinical decision making will be conducted at the same time as the relational care assessment during the in-person simulated Indigenous patient care encounter. Clinical decision making will be assessed using the Adherence to Clinical Practice Guidelines Assessment Tool. This tool has been adapted from a previously piloted tool and adapted to a postpartum context. The maximum score is 24 and a higher score indicates a better outcome. | ClinicalTrials.gov |
| Secondary | Pre-post intervention/control change in implicit Indigenous race preference bias | Pre-assessment done prior to intervention/control training and post assessment done post-Indigenous standardized patient encounter (ie. 11-13 weeks post training intervention) | Implicit bias will be assessed using the Indigenous Peoples of Canada - Implicit Association Test, which will be completed by participants pre and post intervention/control using an online interface. The IPC-IAT has 7 possible categorical outcomes. A reduction in anti-Indigenous race preference bias at follow-up would be considered a positive outcome, if present at baseline. | ClinicalTrials.gov |
| Secondary | Pre-post intervention/control change in explicit anti-Indigenous bias as measured using the Modern Prejudiced Attitudes Towards Aboriginals | Pre-assessment done prior to intervention/control training and post assessment done post-Indigenous standardized patient encounter (ie. 11-13 weeks post training intervention) | Explicit bias will be measured using the Modern Prejudiced Attitudes Towards Aboriginals which will be completed by participants pre and post intervention/control using an online interface. There are 14 items, each item has a 7 point Likert scale. Total score is 98 with higher scores indicating a higher level of prejudice once reverse scaled questions are adjusted. | ClinicalTrials.gov |
| Secondary | Pre-post intervention/control assessed using the Perceived cultural safety competency assessed using the Indigenous Cultural Safety Self-Assessment (ICSSA) tool. | Pre-assessment done prior to intervention/control training and post assessment done post-Indigenous standardized patient encounter (ie. 11-13 weeks post training intervention) | Perceived cultural safety competency will be measured using the Indigenous Cultural Safety Self-Assessment (ICSSA) tool, which will be completed by participants pre and post intervention/control using an online interface. There are 51 questions scaled on a 10 point Likert scale with higher scores indicating higher self assessment Indigenous cultural safety once reverse scaled questions are accounted for. | ClinicalTrials.gov |
| Secondary | Virtual Reality Modality Feasibility and Acceptability | Completed immediately following intervention training (Arm 1) | Participants in the intervention training arm #1 will complete a short paper survey assessing their experience, acceptability, and the feasibility of the VR modality. This self-report survey draws on existing VR feasibility and acceptability assessment tools. This tool has 17 questions scaled on a 7 point Likert scale with higher scores indicating a more positive outcome with the exception of the questions about motion sickness, for which higher scales indicate more motion sickness symptoms. The scale also gathers qualitative information regarding VR feasibility and acceptability. | ClinicalTrials.gov |
| Secondary | Online Education Session Evaluation | Completed immediately following control training (Arm 2) | Participants in the control training arm #2 will complete a time attention matched paper survey evaluating their experience with the online control education session they completed. This survey will gather qualitative text data. | ClinicalTrials.gov |
| Secondary | Pre-post intervention/control change in explicit anti-Indigenous bias as measured using the Motivation to Respond Without Prejudice scales. | Pre-assessment done prior to intervention/control training and post assessment done post-Indigenous standardized patient encounter (ie. 11-13 weeks post training intervention) | Explicit bias will be measured using Motivation to Respond Without Prejudice scales, which will be completed by participants pre and post intervention/control using an online interface. There are ten questions, each with a five point Likert scale. Maximum total score is 50 and a higher score reflects higher motivation to respond without prejudice once reverse scaled questions are accounted for. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 2
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Implicit Association Test (IAT) | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)